Dr. Nagle on the Evolution of Daratumumab Administration in Multiple Myeloma

October 22, 2020
Sarah Nagle, MD

Sarah Nagle, MD, discusses the evolution of daratumumab administration in multiple myeloma.

Sarah Nagle, MD, assistant professor of medicine, School of Medicine, Oregon Health & Science University, discusses the evolution of daratumumab (Darzalex) administration in multiple myeloma.

Historically, daratumumab had a very long administration time, says Nagle. As patients tolerate the infusions, the administration time is shortened.

In May 2020, the FDA approved a subcutaneous formulation of daratumumab and hyaluronidase-fihj (Darzalex Faspro) for use in adult patients with multiple myeloma.

Although patients are monitored for a period of time after receiving the subcutaneous regimen, the transition significantly shortens the administration time of daratumumab, which allows the agent to be more accessible to patients, concludes Nagle.

Related Content:

Onclive TV | Multiple Myeloma

x